At demerger from ICI, industry watchers were suggesting that Zeneca could not survive by going it alone - management then were defiant, today they are optimistic that the strength of the company's cancer drugs and enhanced US presence will push the firm into number one position in this arena by the year 2000. By Susan Royse.